Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Brief Summary: * The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel) in subjects with NSCLC.
* The study is evaluating the safety and tolerability of Nivolumab as maintenance therapy in combination with Bevacizumab/Avastin that will be given after at least 4 cycles of platinum doublet chemotherapy.
* The study is evaluating the safety and tolerability of Nivolumab in combination with Erlotinib among epidermal growth factor receptor (EGFR) mutation positive non-squamous NSCLC subjects and as monotherapy in subjects with NSCLC.
* The study is evaluating the safety and tolerability of Nivolumab in combination with Ipilimumab in subjects with squamous and non-squamous NSCLC.
* The study is evaluating the safety and tolerability of Nivolumab as switch maintenance therapy in subjects with squamous and non-squamous NSCLC.
* The study is evaluating the safety and tolerability of Nivolumab as monotherapy among subjects with untreated, asymptomatic brain metastases and no evidence of cerebral edema.


Options:
A: Arm Label: Arm A: Nivolumab + Gemcitabine + Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Arm B: Nivolumab + Pemetrexed + Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cisplatin, Drug: Pemetrexed | Arm Label: Arm C: Nivolumab + Paclitaxel + Carboplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm D: Nivolumab + Bevacizumab maintenance; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Bevacizumab | Arm Label: Arm E: Nivolumab + Erlotinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Erlotinib | Arm Label: Arm F: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm G: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm H: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm J: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm K: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm L: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm M: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm O: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm P: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm Q: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm R: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm S: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin, Arm B: Nivolumab + Pemetrexed + Cisplatin, Arm C: Nivolumab + Paclitaxel + Carboplatin, Arm D: Nivolumab + Bevacizumab maintenance, Arm E: Nivolumab + Erlotinib, Arm F: Nivolumab, Arm G: Nivolumab + Ipilimumab, Arm H: Nivolumab + Ipilimumab, Arm I: Nivolumab + Ipilimumab, Arm J: Nivolumab + Ipilimumab, Arm K: Nivolumab, Arm L: Nivolumab, Arm M: Nivolumab, Arm N: Nivolumab + Ipilimumab, Arm O: Nivolumab + Ipilimumab, Arm P: Nivolumab + Ipilimumab, Arm Q: Nivolumab + Ipilimumab, Arm R: Nivolumab + Ipilimumab, Arm S: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin, Arm B: Nivolumab + Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B: Nivolumab + Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm D: Nivolumab + Bevacizumab maintenance | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm E: Nivolumab + Erlotinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm G: Nivolumab + Ipilimumab, Arm H: Nivolumab + Ipilimumab, Arm I: Nivolumab + Ipilimumab, Arm J: Nivolumab + Ipilimumab, Arm N: Nivolumab + Ipilimumab, Arm O: Nivolumab + Ipilimumab, Arm P: Nivolumab + Ipilimumab, Arm Q: Nivolumab + Ipilimumab, Arm R: Nivolumab + Ipilimumab, Arm S: Nivolumab + Ipilimumab
B: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Docetaxel 75 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel 75 mg/m^2
C: Arm Label: (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: A